Clinical Study
Testing Inhaled Treprostinil in People with Idiopathic Pulmonary Fibrosis
This study will test new a drug called Inhaled Treprostinil in people with Idiopathic Pulmonary Fibrosis (IPH). IPF is a disease that causes scarring in the lungs. The study wants to see if Inhaled Treprostinil will help people with IPF and is safe. People in this study will be randomly chosen to be treated with Inhaled Treprostinil or placebo. The placebo does not contain any medicine. Treprostinil and placebo are given by breathing the medicine into the lungs using a machine called a nebulizer (inhaling device). The nebulizer changes the medicine into a mist to breathe into the lungs. Being in this study requires about 8 clinic visits. Participation lasts about 58 weeks. Medical visits will be done during the study to track the health of participants.
For more information contact:
Cassie Larsen
cassie.larsen@hsc.utah.edu
801-581-5811
IRB#: IRB_00143600
| PI: Mary Beth Scholand
| Department: PULMONARY
| Approval Date: 2022-08-17 06:00:00
Specialties: Pulmonary
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 40 years and older
- Diagnosis of Idiopathic Pulmonary Fibrosis
- Can be on Pirfenidone or Nintedanib (other drugs given for Idiopathic Pulmonary Fibrosis) started either 30 days or more before study participation
- Able to attend in person at a study clinic
Exclusion Criteria:
- Pregnant or breastfeeding
- Receiving a certain amount of extra oxygen for breathing
- Severe IPF or active lung infection or other infections that affect breathing within 30 days prior to study participation
- Uncontrolled cardiac (heart) disease
Will I be paid for my time?
Yes